title: Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus.
abstract: SRL is a new and potent immunosuppressive agent that has been successfully introduced in organ transplantation. In contrast to other immunosuppressive agents, SRL has a potent antitumor activity both in vitro and in vivo. Herein, we report a child with Kaposi's sarcoma that was diagnosed 30 months after LDLT and treated successfully with only conversion to SRL monotherapy. KS regressed completely at the end of the first month and remained in remission during 28 months follow-up.
authors.affiliation: Pediatric Gastroenterology, Hepatology, and Nutrition, Ege University School of Medicine, Bornova, Izmir, Turkey.
authors.forename: Hasan A
authors.initials: HA
authors.lastname: Yuksekkaya
authors.forename: Cigdem
authors.initials: C
authors.lastname: Arikan
authors.forename: Ayse
authors.initials: A
authors.lastname: Yazici
authors.forename: Masallah
authors.initials: M
authors.lastname: Baran
authors.forename: Sema
authors.initials: S
authors.lastname: Aydogdu
authors.forename: Murat
authors.initials: M
authors.lastname: Kilic
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus